抗体是免疫系统中不可或缺的组成部分，具有广泛的分子靶点。它们被认为是治疗多种疾病的模式，并且已有超过130种获批的基于抗体的治疗药物可供临床使用。然而，在疗效、组织渗透性和安全性方面仍存在限制，特别是在癌症治疗中。纳米颗粒，特别是对外部刺激响应的纳米颗粒，表现出改善基于抗体的治疗药物疗效和组织选择性递送的前景。在本研究中，我们开发了一种可靠准确的方法，通过十二烷基硫酸钠-聚丙烯酰胺凝胶电泳（SDS-PAGE）和银染色，对与治疗HER2阳性癌症的抗体为基础的药物Herceptin®（曲妥珠单抗）修饰的脂质纳米颗粒上负载的抗体量进行定量。这种方法证明是一种适合替代常用脂质干扰样本中存在的蛋白质定量技术的方法。此外，通过这种方法测量到的曲妥珠单抗修饰在脂质体上的量，经过了曲妥珠单抗的抗体依赖细胞介导的细胞毒性活性的确认。我们的结果表明，这种方法具有作为开发组织选择性抗体递送系统的关键工具的潜力，进而提高基于抗体的治疗药物的疗效并减少副作用。版权©2023。由Elsevier B.V.出版。

Antibodies are essential components of the immune system with a wide range of molecular targets. They have been recognized as modalities for treating several diseases and more than 130 approved antibody-based therapeutics are available for clinical use. However, limitations remain associated with its efficacy, tissue permeability, and safety, especially in cancer treatment. Nanoparticles, particularly those responsive to external stimuli, have shown promise in improving the efficacy of antibody-based therapeutics and tissue-selective delivery. In this study, we developed a reliable and accurate method for quantifying the amount of antibody loaded onto lipid nanoparticles modified with Herceptin® (Trastuzumab), an antibody-based therapeutic used to treat HER2-positive cancers, using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) followed by silver staining. This method proved to be a suitable alternative to commonly used protein quantification techniques, which are limited by lipid interference present in the samples. Furthermore, the amount of Herceptin modified on the liposomes, measured by this method, was confirmed by Herceptin's antibody-dependent cell-mediated cytotoxicity activity. Our results demonstrate the potential of this method as a critical tool for developing tissue-selective antibody delivery systems, leading to improved efficacy and reduced side effects of antibody-based therapeutics.Copyright © 2023. Published by Elsevier B.V.